Moore Capital Management, LP Arcus Biosciences, Inc. Transaction History

Moore Capital Management, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $678,800 - $881,200	40,000 New	40,000 $812,000
Q3 2021 Nov 15, 2021	SELL	$26.93 - $37.68 $673,250 - $942,000	-25,000 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$26.16 - $41.39 $261,600 - $413,900	-10,000 Reduced 28.57%	25,000 $702,000
Q2 2020 Aug 14, 2020	BUY	$13.97 - $36.56 $488,950 - $1.28 Million	35,000 New	35,000 $866,000

200

51.5M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.02B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Moore Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Moore Capital Management, LP with notifications on news.